Cart summary

You have no items in your shopping cart.

AGI-1067

SKU: orb1225657

Description

AGI-1067 (Succinobucol) is a potent inhibitor of TNF-α-inducible expression of VCAM-1, MCP-1 and E-selectin (IC50=6,10 and 25 uM) with concurrent antioxidant and lipid-modulating properties; inhibits atherosclerosis in LDL receptor-deficient and apolipoprotein E-deficient mice, also reduces VCAM-1 and MCP-1 mRNA levels in lungs of LPS-stimulated mice; inhibits atherosclerosis not only via its lipid-lowering effects but also by having direct anti-inflammatory effects on the vessel wall.Diabetes Phase 3 Clinical(In Vitro):Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation in rabbit whole blood. Succinobucol also causes a significant reduction in whole blood aggregation in response to ADP. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO. Succinobucol significantly prevents 3-NP-induced loss of SH-SY5Y cell viability, generation of reactive oxygen species, and decrease of ΔΨm. Succinobucol does not protect against 3-NP-induced inhibition of mitochondrial complex II activity, pointing to the mitigation of secondary events resultant from mitochondrial complex II inhibition. Succinobucol significantly increases (50 %) the levels of GSH in SH-SY5Y cells, which is paralleled by significant increases in glutamate cysteine ligase messenger RNA (mRNA) expression and activity. Succinobucol effectively exhibits superior inhibitory effects on cell migration and invasion activities, VCAM-1 expression and cell-cell binding of RAW 264.7 to 4T1 cells. Succinobucol also shows inhibitory effect on VCAM-1 expression in 4T1 cells and cell-cell binding of RAW 264.7 to 4T1 cancer cells.(In Vivo):Succinobucol (50, 100, and 150 mg/kg, i.v.) has no significant effect on either heart rate or MAP, but the blood removed 15 minutes after the final injection of succinobucol shows significantly less aggregation in response to collagen at both 5 μg/mL and 20 μg/mL in rats. Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules in lung metastatic breast cancer mice.

Images & Validation

Key Properties

CAS Number216167-82-7
MW616.916
Purity>98% (HPLC)
FormulaC35H52O5S2
SMILESO=C(O)CCC(OC1=C(C(C)(C)C)C=C(SC(C)(SC2=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C2)C)C=C1C(C)(C)C)=O
TargetOthers
SolubilityDMSO: Soluble ( < 1 mg/ml refers to the product slightly soluble or insoluble )

Bioactivity

In Vivo
Succinobucol (50, 100, and 150 mg/kg, i. v.) has no significant effect on either heart rate or MAP, but the blood removed 15 minutes after the final injection of succinobucol shows significantly less aggregation in response to collagen at both 5 μg/mL and 20 μg/mL in rats. Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules in lung metastatic breast cancer mice.
In Vitro
Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation in rabbit whole blood. Succinobucol also causes a significant reduction in whole blood aggregation in response to ADP. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO. Succinobucol significantly prevents 3-NP-induced loss of SH-SY5Y cell viability, generation of reactive oxygen species, and decrease of ΔΨm. Succinobucol does not protect against 3-NP-induced inhibition of mitochondrial complex II activity, pointing to the mitigation of secondary events resultant from mitochondrial complex II inhibition. Succinobucol significantly increases (50 %) the levels of GSH in SH-SY5Y cells, which is paralleled by significant increases in glutamate cysteine ligase messenger RNA (mRNA) expression and activity. Succinobucol effectively exhibits superior inhibitory effects on cell migration and invasion activities, VCAM-1 expression and cell-cell binding of RAW 264.7 to 4T1 cells. Succinobucol also shows inhibitory effect on VCAM-1 expression in 4T1 cells and cell-cell binding of RAW 264.7 to 4T1 cancer cells.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Succinobucol | AGI 1067 | AGI1067

Similar Products

  • Succinobucol [orb1302985]

    99.96% (May vary between batches)

    216167-82-7

    616.91

    C35H52O5S2

    5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 1 ml x 10 mM (in DMSO), 200 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

AGI-1067 (orb1225657)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
$ 90.00
10 mg
$ 140.00
25 mg
$ 240.00
50 mg
$ 390.00
100 mg
$ 640.00
500 mg
$ 1,370.00